6fw2
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal Structure of human mARC1== | |
| - | + | <StructureSection load='6fw2' size='340' side='right' caption='[[6fw2]], [[Resolution|resolution]] 1.78Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6fw2]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FW2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FW2 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=B3P:2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>B3P</scene>, <scene name='pdbligand=EFK:oxidanyl(oxidanylidene)molybdenum'>EFK</scene>, <scene name='pdbligand=MOO:MOLYBDATE+ION'>MOO</scene>, <scene name='pdbligand=MTE:PHOSPHONIC+ACIDMONO-(2-AMINO-5,6-DIMERCAPTO-4-OXO-3,7,8A,9,10,10A-HEXAHYDRO-4H-8-OXA-1,3,9,10-TETRAAZA-ANTHRACEN-7-YLMETHYL)ESTER'>MTE</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fw2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fw2 OCA], [http://pdbe.org/6fw2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fw2 RCSB], [http://www.ebi.ac.uk/pdbsum/6fw2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fw2 ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/MARC1_HUMAN MARC1_HUMAN]] As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively.<ref>PMID:19053771</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Kubitza, C]] | ||
| + | [[Category: Scheidig, A]] | ||
| + | [[Category: Marc]] | ||
| + | [[Category: Moco]] | ||
| + | [[Category: Molybdenum cofactor]] | ||
| + | [[Category: Mosc]] | ||
| + | [[Category: N-reduction]] | ||
| + | [[Category: Oxidoreductase]] | ||
Revision as of 06:56, 31 October 2018
Crystal Structure of human mARC1
| |||||||||||
Categories: Kubitza, C | Scheidig, A | Marc | Moco | Molybdenum cofactor | Mosc | N-reduction | Oxidoreductase
